Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases

Baratchi, Sara, Kanwar, Rupinder Kaur, Khoshmanesh, Khashayar, Vasu, Punj, Ashok, Chauhan, Hittu, Matta, Parratt, Andrew, Krishnakumar, Subramanian, Sun, Xueying, Sahoo, Sanjeeb K. and Kanwar, Jagat Rakesh 2009, Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases, Current Nanoscience, vol. 5, no. 1, pp. 15-25.

Attached Files
Name Description MIMEType Size Downloads

Title Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases
Author(s) Baratchi, Sara
Kanwar, Rupinder Kaur
Khoshmanesh, Khashayar
Vasu, Punj
Ashok, Chauhan
Hittu, Matta
Parratt, Andrew
Krishnakumar, Subramanian
Sun, Xueying
Sahoo, Sanjeeb K.
Kanwar, Jagat Rakesh
Journal name Current Nanoscience
Volume number 5
Issue number 1
Start page 15
End page 25
Total pages 11
Publisher Bentham Science Publishers Ltd.
Place of publication Bussum, Netherlands
Publication date 2009
ISSN 1573-4137
1875-6786
Keyword(s) Blood-brain barrier
nanotechnology
drug delivery
inflammatory diseases
neurodegenerative diseases
multiple sclerosis
Summary Brain is a delicate organ, isolated from general circulation and characterized by the presence of relatively impermeable endothelial cells with tight junctions, enzymatic activity and the presence of active efflux transporter mechanisms. These formidable obstacles often block drug delivery to the brain across the blood-brain barrier (BBB). Although several promising molecules have the potential in the in vitro settings but lack of in vivo response is probably because the molecule cannot reach the brain in a sufficient concentration. Drug delivery across the BBB is a major limitation in the treatment of central nervous system (CNS) disorders and CNS infections. This review deals with the role of nanobiotechnology in CNS drug delivery, in which three categories of carbon nanotubes, nanowires and nanoparticles (NPs) are explained. The small size of the NPs makes them an ideal choice to penetrate the BBB. Several mechanisms are involved in this process and various strategies are used. There are some concerns about the safety of NP entry in the brain that need to be resolved before human use. Although there is no approved nanotechnology-based CNS drug available the future for such neuro-nanobiotechnology based delivery system developments is promising.

Language eng
Field of Research 110903 Central Nervous System
100703 Nanobiotechnology
100709 Nanomedicine
Socio Economic Objective 920111 Nervous System and Disorders
HERDC Research category C1 Refereed article in a scholarly journal
HERDC collection year 2009
Persistent URL http://hdl.handle.net/10536/DRO/DU:30029248

Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 25 times in TR Web of Science
Scopus Citation Count Cited 29 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 630 Abstract Views, 5 File Downloads  -  Detailed Statistics
Created: Fri, 11 Jun 2010, 12:10:36 EST by Rachel Kabbani

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.